Eli Lilly and Company operates in the healthcare industry, primarily focusing on the discovery, development, and marketing of pharmaceuticals worldwide. Currently, the company holds a strong position with a stable financial background. With a wide array of products targeting various diseases, it shows promise for long-term growth.
Based on our analysis, Eli Lilly maintains a decent overall score amidst strong performance metrics in Return on Equity and Return on Assets.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical ratings indicate a slight improvement in the overall score, reflecting stability over time.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-08-29 | 3 | 4 | 5 | 5 | 1 | 1 | 1 |
| No Date | 0 | 4 | 5 | 5 | 1 | 1 | 1 |
Analysts have set a broad range for the target price with a median value that reflects moderate optimism regarding future stock performance.
| High | Low | Median | Consensus |
|---|---|---|---|
| $1146 | $700 | $770 | $856 |
The sentiment around Eli Lilly's stock is generally positive, with a majority favoring a 'Buy' recommendation.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 32 | |
| Hold | 8 | |
| Sell | 2 | |
| Strong Sell | 0 |
Eli Lilly and Company shows a balanced financial profile with strong potential for continued growth in the pharmaceutical industry. Despite its solid scores in ROE and ROA, the company faces challenges with its debt-to-equity ratio and valuation metrics. With a broad product range and strategic collaborations, Eli Lilly remains a key player in the healthcare sector, but potential investors should consider market dynamics and industry risks.
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.